Recombinant Biotinylated Human CD52 Protein, Fc, Avitag™, 25 µg

Background
CAMPATH-1 antigen, also known as cluster of differentiation 52 (CD52), is a glycoprotein that in humans is encoded by the CD52 gene.It is widely expressed on the cell surface of immune cells, such as mature lymphocytes, natural killer cells (NK), eosinophils, neutrophils, monocytes/macrophages, and dendritic cells (DCs).ligation of cell surface CD52 molecules may offer costimulatory signals for T-cell activation and proliferation.

Source
Recombinant Biotinylated Human CD52, Fc,Avitag (CD2-H82F3) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ser 36 (Accession # P31358-1 ). 
Predicted N-terminus: Gly 25

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 29.7 kDa. The protein migrates as 38-45 kDa under reducing (R) condition, and 66-100 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "Flow cytometry as an alternative to microscopy for the differentiation of bronchoalveolar lavage fluid leukocytes"
Bratke, Weise, Stoll et al
Chest (2024)
(2)  "Alemtuzumab-induced thyroid eye disease successfully treated with a single low-dose of rituximab"
Muller, Maioli, Armenti et al
Eur Thyroid J (2024)
(3)  "Alemtuzumab infusion-associated reactions and laboratory changes in patients with relapsing-remitting multiple sclerosis at baseline and first-year follow-up"
Saridas, Mercan Saridas, Koc et al
Heliyon (2024) 10 (5), e26900
Showing 1-3 of 1256 papers.